Cell line · CVCL_1382
LS1034
Cancer cell line, Homo sapiens. Cecum adenocarcinoma. 45 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. LS1034. Cell lines, record CVCL_1382. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1382
On this page
Cell line
As Cellosaurus gives it.
- Name
- LS1034
- Accession
- CVCL_1382
- RRID
- RRID:CVCL_1382
- Synonyms
- LS 1034, LS-1034
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 54Y
- Category
- Cancer cell line
- Diseases
- Cecum adenocarcinoma (NCIt C5543)
- Derived from
- Cecum (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers45
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Preventive Effect of Butyrate in Colon Cancer Cell Metabolism. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model. | Front Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Subcellular Redistribution of Endomembrane GPR15 Promotes NAD+-Mediated Metabolic Reprogramming and Boosts 5-FU Chemosensitivity in Colorectal Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Synergistic Effects of the Combination of Alpelisib (PI3K Inhibitor) and Ribociclib (CDK4/6 Inhibitor) in Preclinical Colorectal Cancer Models. | Int J Mol Sci | 2024 | Its Methods give the RRID and name the line | PubMed | |
| TR-107, an Agonist of Caseinolytic Peptidase Proteolytic Subunit, Disrupts Mitochondrial Metabolism and Inhibits the Growth of Human Colorectal Cancer Cells. | Mol Cancer Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Exploiting a subtype-specific mitochondrial vulnerability for successful treatment of colorectal peritoneal metastases. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| A Cluster of Evolutionarily Recent KRAB Zinc Finger Proteins Protects Cancer Cells from Replicative Stress-Induced Inflammation. | Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells. | Sci Signal | 2022 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 45
See all 45 papersRelatives1
| Relation | Cell line | Accession | Problem |
|---|---|---|---|
| From the same person | LS1034-PBL | CVCL_VV29 |
Source Cell lines
Cell banks3
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1382
GET https://conductscience.org/api/cell-lines/v1/CVCL_1382/papers?page=2